Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

Clinical trial NCT06399107 · RECRUITING

Trial details

NCT number: NCT06399107
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease Sickle-Cell Disease With Crisis

Start date: 2024-08-01
Primary completion: 2025-11-10
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.